Notice of Closed Meeting, 3453-3454 [2019-01961]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 29 / Tuesday, February 12, 2019 / Notices
Infectious Zoonotic Disease, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mail Stop H16–3,
Atlanta, GA 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Katherine Allen-Bridson, RN, BSN,
MScPH, CIC, National Center for
Emerging and Infectious Zoonotic
Disease, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mail
Stop H16–3, Atlanta, GA 30329. Phone:
404–639–4000; Email:nhsn@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose of the Notice: The purpose of
this notice is to request input and
information from individuals and
organizations on issues and areas for
potential improvement for consideration
as CDC updates and maintains the
NHSN surveillance protocols for 2020.
CDC will carefully consider all
comments with an intent to improve on
and maintain the requirements for a
successful surveillance program:
Acceptable data collection burden,
consistency, sensitivity, specificity,
representativeness, and timeliness. The
CDC reserves the right to respond to
time-sensitive issues outside of this RFI
as needed to maintain the reliability of
the NHSN data.
Scope of Issue: The mission of CDC’s
Division of Healthcare Quality
Promotion (DHQP) is to protect patients
and healthcare personnel and promote
safety, quality, and value in national
and international healthcare delivery
systems. In accordance with this
mission, DHQP seeks to identify
effective prevention methods, foster
their implementation, and measure their
impact on the incidence of healthcareassociated infections (HAIs). Over
21,000 healthcare facilities report data
on HAIs to CDC’s NHSN. This includes
data that CDC reports to the Centers for
Medicare and Medicaid Services (CMS)
on behalf of healthcare facilities. CMS
uses the data in its public reporting and
payment programs.
Approach: CDC seeks information
from NHSN users and stakeholders
regarding the NHSN surveillance
protocols, including comments that
describe specific concerns about and
recommendations for specific changes
regarding the following topics: Protocol
scope, definitions, criteria, data
collection requirements, and other
VerDate Sep<11>2014
18:30 Feb 11, 2019
Jkt 247001
surveillance specifications for the OPC
and BSI module.
Also, CDC is exploring the possibility
of adding a new HAI event to its
surveillance protocols, hospital onset
bacteremia (HOB). The scope of HOB’s
surveillance would be all bloodstream
infections that develop in patients
following hospital admission, i.e., those
bloodstream infections that are not
present on admission. Although this
scope would be wider than Central
Line-associated Bloodstream Infection
(CLABSI) surveillance, CLABSI
surveillance could be incorporated as a
subset of HOB surveillance. CDC seeks
input on NHSN’s current CLABSI
surveillance protocol and potential
work on HOB surveillance.
Potential Areas of Focus: CDC is
interested in receiving information on
issues and areas for potential
improvement for consideration for the
following:
1. Outpatient Procedure Component
surveillance protocol.
2. Patient Safety Component
Bloodstream Infection Module
surveillance protocol.
3. Possible addition of hospital onset
bacteremia (HOB) to NHSN’s
surveillance protocols.
Examples of the types of information
valuable to CDC include:
1. How could the CLABSI and OPC
surveillance protocols and/or
surveillance definitions be improved?
2. What challenges are faced when
applying these definitions? What could
be added to the definitions to address
these challenges?
3. What protocol or data analysis
changes could make the CLABSI or OPC
data more useful?
Dated: February 6, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2019–01915 Filed 2–11–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
3453
the Chief Operating Officer, Centers for
Disease Control and Prevention,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—SIP19–001;
Improving Cognitive Impairment Detection
and Referral to Resources among Older
Adults: Applying the KAER Model in a
Clinical Health Care System.
Dates: April 23, 2019.
Times: 11:00 a.m.–6:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
kva5@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–01960 Filed 2–11–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
E:\FR\FM\12FEN1.SGM
12FEN1
3454
Federal Register / Vol. 84, No. 29 / Tuesday, February 12, 2019 / Notices
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel; (SEP)—SIP19–002,
Managing Epilepsy Well 2.0 (MEW)
Network—Coordinating Center and SIP19–
003, Managing Epilepsy Well 2.0 (MEW)
Network—Collaborating Center.
Dates: April 25, 2019.
Times: 10:00 a.m.–6:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
kva5@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri A. Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–01961 Filed 2–11–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[30Day–19–0048]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Agency for
Toxic Substances and Disease Registry
(ATSDR) has submitted the information
collection request titled ATSDR
Exposure Investigations (EIs) to the
Office of Management and Budget
(OMB) for review and approval. ATSDR
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on November 6, 2018 to obtain
comments from the public and affected
agencies. ATSDR did not receive
comments related to the previous
notice. This notice serves to allow an
additional 30 days for public and
affected agency comments.
ATSDR will accept all comments for
this proposed information collection
project. The Office of Management and
Budget is particularly interested in
comments that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
VerDate Sep<11>2014
19:59 Feb 11, 2019
Jkt 247001
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
ATSDR Exposure Investigations (EIs),
(OMB Control No. 0923–0048,
Expiration Date 3/31/2019)—
Extension—Agency for Toxic
Substances and Disease Registry
(ATSDR).
Background and Brief Description
The Agency for Toxic Substances and
Disease Registry (ATSDR) is requesting
a three-year Paperwork Reduction Act
approval for the extension of the generic
clearance titled ATSDR Exposure
Investigations (OMB No. 0923–0048;
OMB Exp. Date: 3/31/2019) to allow the
agency to conduct exposure
investigations (EIs), through methods
developed by ATSDR.
After a chemical release or suspected
release into the environment, EIs are
usually requested by officials of a state
health agency, county health
departments, the Environmental
Protection Agency (EPA), the general
public, and ATSDR staff.
EI results are used by public health
professionals, environmental risk
managers, and other decision makers to
determine if current conditions warrant
intervention strategies to minimize or
eliminate human exposure. For
example, four of the EIs that ATSDR
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
conducted in the past three years
include the Anaconda Smelter (MT—
blood lead and urine arsenic), Former
United Zinc and Associated Smelters
(KS—blood lead), Dimock Private Well
Water Sampling (PA) and the Follow-up
Arsenic Urine Testing in Hayden,
Arizona.
Example 1: Anaconda Smelter Blood
Lead and Urine Arsenic Sampling, MT
The site is a former smelter located in
Anaconda, Montana. Past smelting
activities resulted in high levels of
heavy metals, primarily arsenic and
lead, in community soil and in the slag
piles. ATSDR sampled blood and urine
in 191 community members to evaluate
lead (blood) and arsenic (urine) in
September 2018. Given community
concern about contamination, all
members of the community were invited
to participate in the testing. Given
community interest in the testing, an
additional round of testing (177
participants) was completed in
November 2018 that focused on
residents that were not tested in the
September event as well as young
children and women of childbearing
age, since they are the most impacted by
lead exposure.
Urine samples were evaluated for
total arsenic, speciated arsenic (organic
and inorganic), creatinine and specific
gravity. If arsenic is detected, speciation
of the sample will determined whether
the arsenic is organic (probably
resulting from eating seafood) or
inorganic (likely resulting from
exposure to environmental arsenic). The
results of the testing are currently being
analyzed by the National Center for
Environmental Health/Division of
Laboratory Sciences (NCEH/DLS). For
the initial testing event, participants
have been notified of their results by
mail; two adult participants with blood
lead levels ≥5 mg/dL were also notified
of their results by phone by the EI
Medical Officer. Results for the followup testing will be sent individually to
participants when the analysis is
completed and a report will be prepared
and presented to the community in a
community meeting.
Example 2: Former United Zinc and
Associated Smelters, Iola, Kansas
The community is located in the
vicinity of the Former United Zinc and
Associated Smelters in Iola, Kansas. The
smelters operated from 1902 to 1925
and operations resulted in heavy metal
contamination in community soils.
Limited sampling of the community in
the past found elevated blood lead
levels (BLLs) in young children. The
blood testing was completed in two
E:\FR\FM\12FEN1.SGM
12FEN1
]]>Agencies
[Federal Register Volume 84, Number 29 (Tuesday, February 12, 2019)]
[Notices]
[Pages 3453-3454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01961]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would
[[Page 3454]]
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel; (SEP)--SIP19-002, Managing
Epilepsy Well 2.0 (MEW) Network--Coordinating Center and SIP19-003,
Managing Epilepsy Well 2.0 (MEW) Network--Collaborating Center.
Dates: April 25, 2019.
Times: 10:00 a.m.-6:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, kva5@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal
Register notices pertaining to announcements of meetings and other
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and
Disease Registry.
Sherri A. Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-01961 Filed 2-11-19; 8:45 am]
BILLING CODE 4163-18-P
